GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of Galadus score

Ju Dong Yang, Benyam D. Addissie, Kristin C. Mara, William S. Harmsen, Jianliang Dai, Ning Zhang, Nicha Wongjarupong, Hawa M. Ali, Hamdi A. Ali, Fatima A. Hassan, Sravanthi Lavu, Jessica L. Cvinar, Nasra H. Giama, Catherine D. Moser, Katsuyuki Miyabe, Loretta K. Allotey, Alicia Algeciras-Schimnich, J. Paul Theobald, Melissa M. Ward, Mindie H. Nguyen & 11 others Alex S. Befeler, K. Rajender Reddy, Myron Schwartz, Denise Harnois, Hiroyuki Yamada, Sudhir Srivastava, Jo Ann Rinaudo, Gregory James Gores, Ziding Feng, Jorge A. Marrero, Lewis Rowland Roberts

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The GALAD score is a serum biomarker–sensitivity of 91% and a specificity of 85% for HCC detection. based model that predicts the probability of having The AUC of the GALAD score for early-stage HCC detection hepatocellular carcinoma (HCC) in patients with chronic remained high at 0.92 (95% CI, 0.88–0.96; cutoff 1.18, liver disease. We aimed to assess the performance of the sensitivity 92%, specificity 79%). The AUC of the GALAD GALAD score in comparison with liver ultrasound for score for HCC detection was 0.88 (95% CI, 0.85–0.91) in the detection of HCC. EDRN cohort. The combination of GALAD and ultrasound Methods: A single-center cohort of 111 HCC patients and (GALADUS score) further improved the performance of the 180 controls with cirrhosis or chronic hepatitis B and a GALAD score in the single-center cohort, achieving an AUC multicenter cohort of 233 early HCC and 412 cirrhosis of 0.98 (95% CI, 0.96–0.99; cutoff 0.18, sensitivity 95%, patients from the Early Detection Research Network (EDRN) specificity 91%). phase II HCC Study were analyzed. Conclusions: The performance of the GALAD score was Results: The area under the ROC curve (AUC) of the GALAD superior to ultrasound for HCC detection. The GALADUS score for HCC detection was 0.95 [95% confidence interval score further enhanced the performance of the GALAD score. (CI), 0.93–97], which was higher than the AUC of ultrasound Impact: The GALAD score was validated in the United (0.82, P <0.01). At a cutoff of 0.76, the GALAD score had a States.

Original languageEnglish (US)
Pages (from-to)531-538
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume28
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Hepatocellular Carcinoma
Liver
ROC Curve
Area Under Curve
Fibrosis
Chronic Hepatitis B
Research
Liver Diseases
Confidence Intervals
Sensitivity and Specificity
Serum

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of Galadus score. / Yang, Ju Dong; Addissie, Benyam D.; Mara, Kristin C.; Harmsen, William S.; Dai, Jianliang; Zhang, Ning; Wongjarupong, Nicha; Ali, Hawa M.; Ali, Hamdi A.; Hassan, Fatima A.; Lavu, Sravanthi; Cvinar, Jessica L.; Giama, Nasra H.; Moser, Catherine D.; Miyabe, Katsuyuki; Allotey, Loretta K.; Algeciras-Schimnich, Alicia; Theobald, J. Paul; Ward, Melissa M.; Nguyen, Mindie H.; Befeler, Alex S.; Reddy, K. Rajender; Schwartz, Myron; Harnois, Denise; Yamada, Hiroyuki; Srivastava, Sudhir; Rinaudo, Jo Ann; Gores, Gregory James; Feng, Ziding; Marrero, Jorge A.; Roberts, Lewis Rowland.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 28, No. 3, 01.03.2019, p. 531-538.

Research output: Contribution to journalArticle

Yang, JD, Addissie, BD, Mara, KC, Harmsen, WS, Dai, J, Zhang, N, Wongjarupong, N, Ali, HM, Ali, HA, Hassan, FA, Lavu, S, Cvinar, JL, Giama, NH, Moser, CD, Miyabe, K, Allotey, LK, Algeciras-Schimnich, A, Theobald, JP, Ward, MM, Nguyen, MH, Befeler, AS, Reddy, KR, Schwartz, M, Harnois, D, Yamada, H, Srivastava, S, Rinaudo, JA, Gores, GJ, Feng, Z, Marrero, JA & Roberts, LR 2019, 'GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of Galadus score', Cancer Epidemiology Biomarkers and Prevention, vol. 28, no. 3, pp. 531-538. https://doi.org/10.1158/1055-9965.EPI-18-0281
Yang, Ju Dong ; Addissie, Benyam D. ; Mara, Kristin C. ; Harmsen, William S. ; Dai, Jianliang ; Zhang, Ning ; Wongjarupong, Nicha ; Ali, Hawa M. ; Ali, Hamdi A. ; Hassan, Fatima A. ; Lavu, Sravanthi ; Cvinar, Jessica L. ; Giama, Nasra H. ; Moser, Catherine D. ; Miyabe, Katsuyuki ; Allotey, Loretta K. ; Algeciras-Schimnich, Alicia ; Theobald, J. Paul ; Ward, Melissa M. ; Nguyen, Mindie H. ; Befeler, Alex S. ; Reddy, K. Rajender ; Schwartz, Myron ; Harnois, Denise ; Yamada, Hiroyuki ; Srivastava, Sudhir ; Rinaudo, Jo Ann ; Gores, Gregory James ; Feng, Ziding ; Marrero, Jorge A. ; Roberts, Lewis Rowland. / GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of Galadus score. In: Cancer Epidemiology Biomarkers and Prevention. 2019 ; Vol. 28, No. 3. pp. 531-538.
@article{f39f1a43a3b94b749b4530a5434371a8,
title = "GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of Galadus score",
abstract = "Background: The GALAD score is a serum biomarker–sensitivity of 91{\%} and a specificity of 85{\%} for HCC detection. based model that predicts the probability of having The AUC of the GALAD score for early-stage HCC detection hepatocellular carcinoma (HCC) in patients with chronic remained high at 0.92 (95{\%} CI, 0.88–0.96; cutoff 1.18, liver disease. We aimed to assess the performance of the sensitivity 92{\%}, specificity 79{\%}). The AUC of the GALAD GALAD score in comparison with liver ultrasound for score for HCC detection was 0.88 (95{\%} CI, 0.85–0.91) in the detection of HCC. EDRN cohort. The combination of GALAD and ultrasound Methods: A single-center cohort of 111 HCC patients and (GALADUS score) further improved the performance of the 180 controls with cirrhosis or chronic hepatitis B and a GALAD score in the single-center cohort, achieving an AUC multicenter cohort of 233 early HCC and 412 cirrhosis of 0.98 (95{\%} CI, 0.96–0.99; cutoff 0.18, sensitivity 95{\%}, patients from the Early Detection Research Network (EDRN) specificity 91{\%}). phase II HCC Study were analyzed. Conclusions: The performance of the GALAD score was Results: The area under the ROC curve (AUC) of the GALAD superior to ultrasound for HCC detection. The GALADUS score for HCC detection was 0.95 [95{\%} confidence interval score further enhanced the performance of the GALAD score. (CI), 0.93–97], which was higher than the AUC of ultrasound Impact: The GALAD score was validated in the United (0.82, P <0.01). At a cutoff of 0.76, the GALAD score had a States.",
author = "Yang, {Ju Dong} and Addissie, {Benyam D.} and Mara, {Kristin C.} and Harmsen, {William S.} and Jianliang Dai and Ning Zhang and Nicha Wongjarupong and Ali, {Hawa M.} and Ali, {Hamdi A.} and Hassan, {Fatima A.} and Sravanthi Lavu and Cvinar, {Jessica L.} and Giama, {Nasra H.} and Moser, {Catherine D.} and Katsuyuki Miyabe and Allotey, {Loretta K.} and Alicia Algeciras-Schimnich and Theobald, {J. Paul} and Ward, {Melissa M.} and Nguyen, {Mindie H.} and Befeler, {Alex S.} and Reddy, {K. Rajender} and Myron Schwartz and Denise Harnois and Hiroyuki Yamada and Sudhir Srivastava and Rinaudo, {Jo Ann} and Gores, {Gregory James} and Ziding Feng and Marrero, {Jorge A.} and Roberts, {Lewis Rowland}",
year = "2019",
month = "3",
day = "1",
doi = "10.1158/1055-9965.EPI-18-0281",
language = "English (US)",
volume = "28",
pages = "531--538",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of Galadus score

AU - Yang, Ju Dong

AU - Addissie, Benyam D.

AU - Mara, Kristin C.

AU - Harmsen, William S.

AU - Dai, Jianliang

AU - Zhang, Ning

AU - Wongjarupong, Nicha

AU - Ali, Hawa M.

AU - Ali, Hamdi A.

AU - Hassan, Fatima A.

AU - Lavu, Sravanthi

AU - Cvinar, Jessica L.

AU - Giama, Nasra H.

AU - Moser, Catherine D.

AU - Miyabe, Katsuyuki

AU - Allotey, Loretta K.

AU - Algeciras-Schimnich, Alicia

AU - Theobald, J. Paul

AU - Ward, Melissa M.

AU - Nguyen, Mindie H.

AU - Befeler, Alex S.

AU - Reddy, K. Rajender

AU - Schwartz, Myron

AU - Harnois, Denise

AU - Yamada, Hiroyuki

AU - Srivastava, Sudhir

AU - Rinaudo, Jo Ann

AU - Gores, Gregory James

AU - Feng, Ziding

AU - Marrero, Jorge A.

AU - Roberts, Lewis Rowland

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background: The GALAD score is a serum biomarker–sensitivity of 91% and a specificity of 85% for HCC detection. based model that predicts the probability of having The AUC of the GALAD score for early-stage HCC detection hepatocellular carcinoma (HCC) in patients with chronic remained high at 0.92 (95% CI, 0.88–0.96; cutoff 1.18, liver disease. We aimed to assess the performance of the sensitivity 92%, specificity 79%). The AUC of the GALAD GALAD score in comparison with liver ultrasound for score for HCC detection was 0.88 (95% CI, 0.85–0.91) in the detection of HCC. EDRN cohort. The combination of GALAD and ultrasound Methods: A single-center cohort of 111 HCC patients and (GALADUS score) further improved the performance of the 180 controls with cirrhosis or chronic hepatitis B and a GALAD score in the single-center cohort, achieving an AUC multicenter cohort of 233 early HCC and 412 cirrhosis of 0.98 (95% CI, 0.96–0.99; cutoff 0.18, sensitivity 95%, patients from the Early Detection Research Network (EDRN) specificity 91%). phase II HCC Study were analyzed. Conclusions: The performance of the GALAD score was Results: The area under the ROC curve (AUC) of the GALAD superior to ultrasound for HCC detection. The GALADUS score for HCC detection was 0.95 [95% confidence interval score further enhanced the performance of the GALAD score. (CI), 0.93–97], which was higher than the AUC of ultrasound Impact: The GALAD score was validated in the United (0.82, P <0.01). At a cutoff of 0.76, the GALAD score had a States.

AB - Background: The GALAD score is a serum biomarker–sensitivity of 91% and a specificity of 85% for HCC detection. based model that predicts the probability of having The AUC of the GALAD score for early-stage HCC detection hepatocellular carcinoma (HCC) in patients with chronic remained high at 0.92 (95% CI, 0.88–0.96; cutoff 1.18, liver disease. We aimed to assess the performance of the sensitivity 92%, specificity 79%). The AUC of the GALAD GALAD score in comparison with liver ultrasound for score for HCC detection was 0.88 (95% CI, 0.85–0.91) in the detection of HCC. EDRN cohort. The combination of GALAD and ultrasound Methods: A single-center cohort of 111 HCC patients and (GALADUS score) further improved the performance of the 180 controls with cirrhosis or chronic hepatitis B and a GALAD score in the single-center cohort, achieving an AUC multicenter cohort of 233 early HCC and 412 cirrhosis of 0.98 (95% CI, 0.96–0.99; cutoff 0.18, sensitivity 95%, patients from the Early Detection Research Network (EDRN) specificity 91%). phase II HCC Study were analyzed. Conclusions: The performance of the GALAD score was Results: The area under the ROC curve (AUC) of the GALAD superior to ultrasound for HCC detection. The GALADUS score for HCC detection was 0.95 [95% confidence interval score further enhanced the performance of the GALAD score. (CI), 0.93–97], which was higher than the AUC of ultrasound Impact: The GALAD score was validated in the United (0.82, P <0.01). At a cutoff of 0.76, the GALAD score had a States.

UR - http://www.scopus.com/inward/record.url?scp=85062417305&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062417305&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-18-0281

DO - 10.1158/1055-9965.EPI-18-0281

M3 - Article

VL - 28

SP - 531

EP - 538

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 3

ER -